Compare AbbVie Inc (ABBV) vs United Parcel Service Inc (UPS) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbbVie Inc vs United Parcel Service Inc — how do they compare? AbbVie Inc trades at $254.01 (market cap $449.91B), while United Parcel Service Inc trades at $109.31 (market cap $95.17B). The key difference: AbbVie Inc is far larger — about 4.7× United Parcel Service Inc's market cap, and United Parcel Service Inc pays the higher dividend (5.86%). Which is the better fit depends on your goals.
| ABBV | UPS | |
|---|---|---|
Market Cap | $449.91B | $95.17B |
Sector | Health | Industrials |
52-Week High | $261.07 | $120.00 |
52-Week Low | $184.85 | $82.58 |
Enterprise Value | $513.38B | $118.03B |
Dividend Yield | 2.72% | 5.86% |
Volume | — | 2,288,643 |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $254.44, showing slight daily weakness but maintaining a bullish technical structure with strong institutional support. The company has consistently beaten earnings expectations in recent quarters, with Q1 2026 EPS of $2.65 exceeding the $2.59 estimate. Revenue growth is accelerating, reaching $61.16B in 2025, while the immunology portfolio (Skyrizi, Rinvoq) successfully offsets Humira declines. Analyst consensus remains strongly positive with 68% buy ratings and a $266.33 price target.
The outlook is constructive with robust pipeline developments and dividend growth, though elevated valuation multiples (P/E 124.83, P/B 245.29) and looming patent cliffs in the 2030s present risks. Net income margin compression from 20.38% in 2022 to 6.9% in 2025 requires monitoring, but strong cash generation ($19.03B operating cash flow) supports continued shareholder returns.
UPS trades at $111.96, up 1.15% with a bullish technical signal. Recent earnings beat expectations (Q1 2026 EPS of $1.07 vs. $1.02 expected), though revenue declined to $88.66B in 2025. The company invests in healthcare logistics and AI to boost efficiency. Valuation ratios appear reasonable with P/E of 17.8 and P/S of 1.06. Analyst consensus is mixed with 42% buy ratings and a $111 price target.
Outlook: UPS faces revenue pressure but maintains solid profitability (ROE 33.41%). Strategic investments in temperature-controlled facilities and AI could drive growth. Risks include competitive threats and economic sensitivity. The stock offers stability with dividend income, but upside may be limited near the consensus target.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About United Parcel Service Inc
United Parcel Service, Inc. (UPS) delivers packages and documents throughout the United States and in other countries and territories. The Company also provides global supply chain services and less-than-truckload transportation, primarily in the US UPS's business consists of integrated air and ground pick-up and delivery network
Read more on UPS →
